Arrowhead Pharmaceuticals Inc Earnings

The next earnings date for Arrowhead Pharmaceuticals Inc is December 1, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Arrowhead Pharmaceuticals Inc Earnings

Report Date	Estimated Earnings Per Share
12/01/2025	$-0.18

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Arrowhead Pharmaceuticals Inc Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
08/07/2025	---	$0	100.00%
05/07/2025	Before Market	$2.75	694.98%
02/04/2025	Before Market	$-1.39	-92.15%
11/27/2024	Before Market	$-1.37	-48.59%
08/08/2024	After Market	$-1.38	-150.91%
05/09/2024	After Market	$-1.02	-537.50%
02/06/2024	After Market	$-1.24	-51.22%
11/29/2023	After Market	$-1.02	-70.00%
08/07/2023	After Market	$-0.96	-47.69%
05/02/2023	After Market	$0.45	170.31%
02/06/2023	After Market	$-0.39	-188.64%
11/28/2022	After Market	$-0.81	-376.47%
08/04/2022	After Market	$-0.68	-33.33%
05/10/2022	After Market	$0.41	612.50%
02/02/2022	After Market	$-0.60	-33.33%
11/22/2021	After Market	$-0.61	-454.55%
08/05/2021	After Market	$-0.29	-45.00%
05/04/2021	After Market	$-0.26	-100.00%
02/04/2021	After Market	$-0.20	-266.67%
11/23/2020	After Market	$-0.48	-500.00%
08/05/2020	After Market	$-0.13	-8.33%
05/07/2020	After Market	$-0.20	-81.82%
02/05/2020	After Market	$-0.03	-200.00%
11/25/2019	After Market	$0.11	-31.25%
08/05/2019	After Market	$0.21	-27.59%
05/08/2019	After Market	$0.24	26.32%
02/07/2019	After Market	$0.13	-75.93%
12/11/2018	After Market	$-0.12	-9.09%
08/07/2018	After Market	$-0.18	0.00%
05/08/2018	After Market	$-0.18	0.00%
02/09/2018	After Market	$-0.18	-12.50%
12/12/2017	After Market	$-0.15	-50.00%
08/03/2017	After Market	$-0.07	50.00%
05/03/2017	After Market	$-0.08	33.33%
02/06/2017	After Market	$-0.17	15.00%
12/14/2016	After Market	$-0.34	-70.00%
08/09/2016	After Market	$-0.32	13.51%
05/10/2016	After Market	$-0.35	5.41%
02/09/2016	After Market	$-0.32	21.95%
12/14/2015	After Market	$-0.41	-5.13%
08/04/2015	After Market	$-0.27	28.95%
05/11/2015	After Market	$-0.33	2.94%
02/09/2015	After Market	$-0.41	-20.59%
11/25/2014	After Market	$-0.33	-37.50%
08/12/2014	---	$-0.22	0.00%
05/06/2014	---	$-0.31	-55.00%
02/04/2014	---	$-0.28	-40.00%
12/18/2013	---	$-0.38	-111.11%
08/08/2013	---	$-0.23	---
05/10/2013	---	$-0.41	---
02/14/2013	---	$-0.33	---
12/21/2012	---	$-0.48	---
08/13/2012	---	$-0.71	---
05/08/2012	---	$-0.50	---
02/10/2012	---	$-0.25	---
12/20/2011	---	$-0.35	---
08/09/2011	---	$-0.25	---
05/13/2011	---	$0.37	---
02/11/2011	---	$-0.20	---
12/23/2010	---	$-0.31	---
08/12/2010	---	$-0.10	77.78%
05/13/2010	---	$-0.30	26.83%
02/11/2010	---	$-0.30	45.45%
12/23/2009	---	$-0.77	---
08/11/2009	---	$-0.58	---
05/15/2009	---	$-1.23	---
02/10/2009	---	$-1.87	---
12/16/2008	---	$-2.14	---
09/03/2008	---	$-1.93	---
05/28/2008	---	$-1.47	---
02/11/2008	---	$-2.11	---
08/29/2007	---	$-3.43	---
02/28/2007	---	$-1.08	---
11/29/2006	---	$-2.58	---
08/30/2006	---	$-1.18	---
05/31/2006	---	$-0.97	---
03/01/2006	---	$-1.12	---
11/30/2005	---	$-0.51	---

More About Arrowhead Pharmaceuticals Inc

Website

https://arrowheadpharma.com

Country

USA

Full Time Employees

609

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.

“Arrowhead Pharmaceuticals Inc Earnings” Can Refer to the Arrowhead Pharmaceuticals Inc Earnings Date

Some people say “Arrowhead Pharmaceuticals Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Arrowhead Pharmaceuticals Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Arrowhead Pharmaceuticals Inc Stock on the Earnings Date

If you own Arrowhead Pharmaceuticals Inc stock (ARWR) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Arrowhead Pharmaceuticals Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Arrowhead Pharmaceuticals Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Arrowhead Pharmaceuticals Inc Earnings

You can contact us any time if you would like to ask questions about Arrowhead Pharmaceuticals Inc earnings or anything else related to the stock market.